Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRO I.V. vs METROGEL-VAGINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Treatment of intra-abdominal infections (e.g., peritonitis, abscess),Treatment of pelvic inflammatory disease,Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (intestinal and extraintestinal),Treatment of anaerobic infections (e.g., bone and joint, central nervous system, respiratory tract, skin and soft tissue),Perioperative prophylaxis (colorectal surgery),Off-label: Helicobacter pylori eradication (with other agents), rosacea (topical), Crohn's disease (perianal fistulas)
Treatment of bacterial vaginosis (FDA-approved),Off-label: Trichomoniasis, anaerobic bacterial infections
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Metronidazole is extensively metabolized in the liver via oxidation and glucuronidation. The major metabolic pathways involve hydroxylation and side-chain oxidation, mediated by CYP450 enzymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4). The primary metabolites are 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-acetic acid, which have minimal antimicrobial activity.
Hepatic metabolism via oxidation and glucuronidation; major metabolite: hydroxy-metronidazole (active).
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
<20%, primarily to albumin.
<20% bound; primarily to serum albumin (minimal binding)
0.6-0.7 L/kg; indicates extensive distribution into tissues including CSF and abscess cavities.
0.25-0.85 L/kg (widely distributed to tissues, including vaginal mucosa and cerebrospinal fluid)
Oral: 80-90%; IV: 100%.
Intravaginal: Systemic bioavailability approximately 50-60% relative to oral; vaginal absorption variable (mean ~56% of oral dose)
Cr Cl > 50 m L/min: no adjustment; Cr Cl 10-50 m L/min: increase dosing interval to every 12 hours; Cr Cl < 10 m L/min: increase interval to every 24 hours.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
No specific Child-Pugh based adjustments available. Use with caution in severe hepatic impairment due to potential metronidazole accumulation.
Loading dose: 15-30 mg/kg IV; maintenance: 7.5 mg/kg IV every 6 hours. For neonates < 7 days: 15 mg/kg IV every 24 hours; 7-28 days: 15 mg/kg IV every 12 hours.
Safety and efficacy not established in pediatric patients; data insufficient for weight-based dosing.
Use with caution; adjust dose based on renal function (Cr Cl) and monitor for neurotoxicity. Start at lower end of dosing range.
No specific dose adjustment required. Use standard dosing with consideration of age-related decline in renal function and potential for concurrent medications.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. It should be used only for approved indications and for the shortest duration necessary.
No FDA boxed warning.
Carcinogenicity: Avoid unnecessary use,Peripheral neuropathy: Risk with high doses or prolonged treatment; discontinue if signs occur,Central nervous system effects: Encephalopathy, convulsions, aseptic meningitis; discontinue if symptoms develop,Hepatotoxicity: Risk of severe hepatic injury, including acute liver failure; monitor liver function,Blood dyscrasias: Leukopenia, neutropenia; caution in patients with history of blood disorders,Interaction with alcohol: Disulfiram-like reaction (nausea, vomiting, flushing); avoid alcohol during therapy and for at least 3 days after,Cochrane interaction: Increased INR with warfarin; monitor INR,Renal impairment: Accumulation of metabolites; dosage adjustment may be needed,Prolonged therapy: Monitor for superinfection and neurological symptoms
Carcinogenicity: Avoid unnecessary prolonged use; rodent studies showed tumorigenicity.,Peripheral neuropathy: May occur with high doses or prolonged therapy.,Candidiasis: May overgrow Candida; treat concurrent infections.,Neutropenia: Monitor CBC if retreatment needed.,Alcohol interaction: Disulfiram-like reaction (abdominal cramps, nausea, vomiting) if alcohol consumed within 48 hours.,Hepatic impairment: Use with caution; dose adjustment may be needed.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (unless alternative treatments not available),Breastfeeding (withhold nursing for 12-24 hours after dose),Concurrent use of disulfiram (psychotic reactions may occur),Severe hepatic impairment (metronidazole is hepatically cleared)
Hypersensitivity to metronidazole or nitroimidazoles,Pregnancy: Contraindicated in first trimester (use only if clearly needed in second/third trimester),Use with alcohol or propylene glycol,Use with disulfiram (within 2 weeks)
No significant food interactions. However, alcohol is strictly contraindicated. Use alcohol-free formulations of medications and avoid alcoholic beverages.
Avoid alcohol and any products containing alcohol (e.g., certain sauces, vinegars, desserts, mouthwashes) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions.
Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.
Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations, but some studies suggest a possible association with cleft lip/palate; use only if clearly needed. In the second and third trimesters, no increased risk of fetal abnormalities has been reported. Avoid use in preterm labor or premature rupture of membranes due to potential systemic absorption.
Excreted in breast milk in low concentrations; M/P ratio approximately 1.0. Considered compatible with breastfeeding; monitor infant for diarrhea or candidiasis.
Metronidazole is excreted in breast milk; after vaginal administration, systemic absorption is minimal (approximately 2% of oral dose), resulting in low milk concentrations. The M/P ratio is approximately 0.8-1.0 for oral dosing; for vaginal gel, ratio is expected lower. The American Academy of Pediatrics considers single-dose therapy compatible with breastfeeding after timed dosing and discarding milk for 12-24 hours. For chronic use, monitor infant for gastrointestinal disturbances.
No specific dose adjustment required in pregnancy; pharmacokinetics not significantly altered. Use standard dosing based on infection severity and renal function.
No dose adjustment is required for METROGEL-VAGINAL during pregnancy. Systemic absorption is low (<2%), and pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose modification for vaginal administration. Use standard dosage: one applicatorful (5 g containing 37.5 mg metronidazole) intravaginally once or twice daily for 5 days.
METRO I. V. (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It has excellent bioavailability following intravenous administration. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). May cause metallic taste, which is benign. Use with caution in patients with CNS disorders due to risk of seizures.
Metronidazole vaginal gel is first-line for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Use caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. May cause metallic taste. Do not use during menstruation; treatment is typically 5 days but can be extended to 7-10 days for recurrent BV.
Do not drink any alcohol or take products containing alcohol (e.g., mouthwash, cough syrup) while using this medication and for 48 hours after stopping, as it can cause severe nausea, vomiting, headache, and abdominal cramps.,May cause a metallic or bitter taste in the mouth; this is harmless and temporary.,Report any numbness, tingling, or weakness in your arms or legs to your healthcare provider immediately, as this could be a sign of nerve damage.,Take the full course of therapy exactly as prescribed, even if you feel better.,If you have severe liver disease, your dose may need to be adjusted.
Use the applicator to insert the gel into the vagina as directed, usually once or twice daily for 5 days.,Do not drink alcohol or use alcohol-containing products (mouthwash, cough syrup) during treatment and for 2 days after stopping.,You may notice a metallic taste in your mouth, which is common and harmless.,Avoid sexual intercourse or use condoms during treatment to prevent irritation and reinfection.,Wash hands before and after use. Do not use tampons, douches, or other vaginal products during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRO I.V. vs METROGEL-VAGINAL, answered by our medical review team.
METRO I.V. is a Antibiotic (Nitroimidazole) that works by Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.. METROGEL-VAGINAL is a Antibiotic (Nitroimidazole) that works by Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRO I.V. and METROGEL-VAGINAL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRO I.V. is: 15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.. The standard adult dose of METROGEL-VAGINAL is: One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRO I.V. and METROGEL-VAGINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRO I.V. is classified as Category C. Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.. METROGEL-VAGINAL is classified as Category C. Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.